Trypanosoma cruzi strains resistant to benznidazole occurring in Colombia
Abstract
Introduction. Chagas disease caused by Trypanosoma cruzi is one of the most serious public health problems in the Americas. Benznidazole is one of two drugs used to treat Chagas’ disease. However, the variation in susceptibility of the parasite to this drug is one of the main causes of treatment failure.
Objective. The in vitro susceptibility to benznidazole was assessed in Colombian strains of T. cruzi from several sources and geographical regions.
Materials and methods. Thirty-three Colombian T. cruzi strains were isolated from humans, vectors and mammals. These were analyzed in vitro by the MTT enzymatic micromethod to determine the IC50 to benznidazole. Additionally, the in vitro susceptibility was correlated with several biological and ecoepidemiological parameters.
Results. Thirty-six percent of the strains were considered to be sensitive, 48% partially resistant, and 16% were resistant. Correlations between the IC50 and several biological and eco-epidemiological parameters indicated that differences in susceptibility depended on the biological source and geographical origin of the strain.
Conclusions. A high degree of variability exists in the susceptibility to benznidazole of T. cruzi strains in Colombia. The distribution data indicate the presence and circulation of naturally resistant strains.
Downloads
References
Pinto-Dias J, Schofield C. Social and medical aspects: Morbidity and mortality in general population. En: Telleria J, Tibayrenc M, editors. American trypanosomiasis Chagas disease. One hundred years of research. First edition. London: Elsevier; 2010. p. 45-54.
Patterson J, Guhl F. Geographical distribution of Chagas disease. En: Telleria J, Tibayrenc M, editors. American trypanosomiasis Chagas disease. One hundred years of research. First edition. London: Elsevier; 2010. p. 83-114.
Moncayo A, Silveira A. Current trends and future prospects for control of Chagas disease. En: Telleria J, Tibayrenc M, editors. American trypanosomiasis Chagas disease. One hundred years of research. First edition. London: Elsevier; 2010. p. 55-82.
Moncayo A. Chagas disease: Current epidemiological trends after the interruption of vectorial and transfusional transmission in the Southern Cone countries. Mem Inst Oswaldo Cruz. 2003;98:577-91. doi: http://dx.doi.org/10.1590/S0074-02762003000500001
López-Antuñano FJ. Quimioterapia de las infecciones producidas por Trypanosoma cruzi. Salud Pública Mex. 1997;39:463-71. doi: http://dx.doi.org/10.1590/S0036-36341997000500009
Rodrigues J, Castro S. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz. 2002;97:3-24. doi: http://dx.doi.org/10.1590/S0074-02762002000100001
Wilkinson SR, Kelly JM. Trypanocidal drugs: Mechanisms, resistance and new targets. Expert Rev Mol Med. 2009;11:1-24.doi: http://dx.doi.org/10.1017/S1462399409001252
Filardi LS, Brener Z. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans R Soc Trop Med Hyg. 1987;81:755-9. doi: http://dx.doi.org/10.1016/0035-9203(87)90020-4
Hayes JD, Wolf CR. Molecular mechanisms of drug resistance. Biochem J. 1990;272:281-95. PMid:1980062 PMCid:1149697
Ouellette M. Biochemical and molecular mechanisms of drug resistance in parasites. Trop Med Int Health. 2001;6:874-82. doi: http://dx.doi.org/10.1046/j.1365-3156.2001.00777.x
Singh N. Drug resistance mechanisms in clinical isolates of Leishmania donovani. Indian J Med Res. 2006;123:411-22. PMid:16778320
Mejía-Jaramillo AM, Fernández GJ, Palacio L, Triana O. Gene expression study using real-time PCR identifies an NTR gene as a major marker of resistance to beznidazole in Trypanosoma cruzi. Parasit Vectors. 2011;4:1-12. PMid:21205315 MCid:3043528
Wilkinson SR, Taylor MC, Horn D, Kelly JM, Cheeseman I. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc Natl Acad Sci USA. 2008;105:5022-7. doi: http://dx.doi.org/10.1073/pnas.0711014105
Villarreal D, Nirde P, Hide M, Barnabe C, Tibayrenc M. Differential gene expression in benznidazole-resistant Trypanosoma cruzi parasites. Antimicrob Agents Chemother. 2005;49:2701-9. doi: http://dx.doi.org/10.1128/AAC.49.7.2701-2709.2005
Nirdé P, Larroque C, Barnabé C. Drug-resistant epimastigotes of Trypanosoma cruzi and persistence of this phenotype after differentiation into amastigotes. C R Acad Sci Ser. 1995;318:1239-44.
Andrade HM, Murta SM, Chapeaurouge A, Perales J, Nirdé P, Romanha AJ. Proteomic analysis of Trypanosoma cruzi resistance to benznidazole. J Proteome Res. 2008;7:2357-67. doi: http://dx.doi.org/10.1021/pr700659m
Campos FM, Liarte DB, Mortara RA, Romanha AJ, Murta SM. Characterization of a gene encoding alcohol dehydrogenase in benznidazole-susceptible and -resistant populations of Trypanosoma cruzi. Acta Trop. 2009;111:56-63. doi: http://dx.doi.org/10.1016/j.actatropica.2009.02.007
Murta SM, Krieger MA, Montenegro LR, Campos FF, Probst CM, Avila AR, et al. Deletion of copies of the gene encoding old yellow enzyme (TcOYE), a NAD(P) H flavin oxidoreductase, associates with in vitro-induced benznidazole resistance in Trypanosoma cruzi. Mol Biochem Parasitol. 2006;146:151-62. doi: http://dx.doi.org/10.1016/j.molbiopara.2005.12.001
Murta SM, Nogueira FB, dos Santos PF, Campos FF, Volpe C, Liarte DB, et al. Differential gene expression in Trypanosoma cruzi populations susceptible and resistant to benznidazole. Acta Trop. 2008;107:59-65. doi: http://dx.doi.org/10.1016/j.actatropica.2008.04.011
Nogueira FB, Krieger MA, Nirde P, Goldenberg S, Romanha AJ, Murta SM. Increased expression of ironcontaining superoxide dismutase-A (TcFeSOD-A) enzyme in Trypanosoma cruzi population with in vitro-induced resistance to benznidazole. Acta Trop. 2006;100:119-32. doi: http://dx.doi.org/10.1016/j.actatropica.2006.10.004
Nogueira FB, Ruiz JC, Robello C, Romanha AJ, Murta SM. Molecular characterization of cytosolic and mitochondrial tryparedoxin peroxidase in Trypanosoma cruzi populations susceptible and resistant to benznidazole. Parasitol Res. 2009;104:835-44. doi: http://dx.doi.org/10.1007/s00436-008-1264-1
Villarreal D, Barnabe C, Sereno D, Tibayrenc M. Lack of correlation between in vitro susceptibility to benznidazole and phylogenetic diversity of Trypanosoma cruzi, the agent of Chagas disease. Exp Parasitol. 2004;108:24-31. doi: http://dx.doi.org/10.1016/j.exppara.2004.07.001
Murta SM, Gazzinelli RT, Brener Z, Romanha AJ. Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox. Mol Biochem Parasitol. 1998;93:203-14. doi: http://dx.doi.org/10.1016/S0166-6851(98)00037-1
Guhl F, Nicholls R, Montoya R, Rosas F, Velasco V, Mora E, et al. Rapid negativization of serology after treatment with benznidazole for Chagas disease in a group of Colombian schoolchildren. Proceedings of the IX European Multicolloquim of Parasitology. Valencia: Medimond International Proceedings; 2004. p. 107-14.
Padilla J. Situación de la enfermedad de Chagas en Colombia. Primer Taller Internacional Sobre Control de la Enfermedad de Chagas, Curso de diagnóstico, manejo y tratamiento de la enfermedad de Chagas, VI Reunión de la Iniciativa Andina para el Control de la Enfermedad de Chagas. Bogotá: CIMPAT; 2005. p. 19-22.
Guhl F, Angulo V, Restrepo M, Nicholls S, Montoya R. Estado del arte de la enfermedad de Chagas en Colombia y estrategias de control. Biomédica. 2003;23:31-3. PMid:12696397
Reed GF, Lynn F, Meade BD. Use of coefficient of variation in assessing variability of quantitative assays. Clin Diagn Lab Immunol. 2002;9:1235-9. PMid:12414755 PMCid:130103
Guhl F, Lazdins-Helds J. Grupo de trabajo científico sobre la enfermedad de Chagas. Buenos Aires: Organización Mundial de la Salud; 2007.
Urbina JA, Docampo R. Specific chemotherapy of Chagas disease: Controversies and advances. Trends Parasitol. 2003;19:495-501. doi: http://dx.doi.org/10.1016/j.pt.2003.09.001
Buckner FS, Navabi N. Advances in Chagas disease drug development: 2009-2010. Curr Opin Infect Dis. 2010; 23:609-16. doi: http://dx.doi.org/10.1097/QCO.0b013e3283402956
Boiani M, Boiani L, Merlino A, Hernández P, Chidichimo A, Cazzulo JJ, et al. Second generation of 2H-benzimidazole 1,3-dioxide derivatives as anti-trypanosomatid agents: Synthesis, biological evaluation, and mode of action studies. Eur J Med Chem. 2009;44:4426-33. doi: http://dx.doi.org/10.1016/j.ejmech.2009.06.014
Boiani M, Piacenza L, Hernández P, Boiani L, Cerecetto H, González M, et al. Mode of action of nifurtimox and N-oxide-containing heterocycles against Trypanosoma cruzi: Is oxidative stress involved? Biochem Pharmacol. 2010;79:1736-45. doi: http://dx.doi.org/10.1016/j.bcp.2010.02.009
Castro D, Boiani L, Benítez D, Hernández P, Merlino A, Gil C, et al. Anti-trypanosomatid benzofuroxans and deoxygenated analogues: Synthesis using polymersupported triphenylphosphine, biological evaluation and mechanism of action studies. Eur J Med Chem. 2009;44:5055-65. doi: http://dx.doi.org/10.1016/j.ejmech.2009.09.009
Gerpe A, Álvarez G, Benítez D, Boiani L, Quiroga M, Hernández P, et al. 5-Nitrofuranes and 5-nitrothiophenes with anti-Trypanosoma cruzi activity and ability to accumulate squalene. Bioorg Med Chem. 2009;17:7500-9. doi: http://dx.doi.org/10.1016/j.bmc.2009.09.013
Gerpe A, Boiani L, Hernández P, Sortino M, Zacchino S, González M, et al. Naftifine-analogues as anti-Trypanosoma cruzi agents. Eur J Med Chem. 2010;45:2154-64. doi: http://dx.doi.org/10.1016/j.ejmech.2010.01.052
Pagano M, Demoro B, Toloza J, Boiani L, González M, Cerecetto H, et al. Effect of ruthenium complexation on trypanocidal activity of 5-nitrofuryl containing thiosemicarbazones. Eur J Med Chem. 2009;44:4937-43. doi: http://dx.doi.org/10.1016/j.ejmech.2009.08.008
Rodríguez J, Arán VJ, Boiani L, Olea-Azar C, Lavaggi ML, González M, et al. New potent 5-nitroindazole derivatives as inhibitors of Trypanosoma cruzi growth: Synthesis, biological evaluation, and mechanism of action studies. Bioorg Med Chem. 2009;17:8186-96. doi: http://dx.doi.org/10.1016/j.bmc.2009.10.030
Urbina JA. Specific chemotherapy of Chagas disease: Relevance, current limitations and new approaches. Acta Trop. 2010;115:55-68. doi: http://dx.doi.org/10.1016/j.actatropica.2009.10.023
Maya JD, Cassels BK, Iturriaga-Vásquez P, Ferreira J, Faundez M, Galanti N, et al. Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comp Biochem Physiol A Mol Integr Physiol. 2007;146:601-20. doi: http://dx.doi.org/10.1016/j.cbpa.2006.03.004
Maya JD, Bollo S, Núñez-Vergara LJ, Squella JA, Repetto Y, Morello A, et al. Trypanosoma cruzi: Effect and mode of action of nitroimidazole and nitrofuran derivatives. Biochem Pharmacol. 2003;65:999-1006. doi: http://dx.doi.org/10.1016/S0006-2952(02)01663-5
Hall BS, Wu X, Hu L, Wilkinson SR. Exploiting the drugactivating properties of a novel trypanosomal nitroreductase. Antimicrob Agents Chemother. 2010;54:1193-9. doi: http://dx.doi.org/10.1128/AAC.01213-09
Hall BS, Bot C, Wilkinson SR. Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites. J Biol Chem. 2011;286:13088-95. doi: http://dx.doi.org/10.1074/jbc.M111.230847
Toledo MJ, Bahia MT, Carneiro CM, Martins-Filho OA, Tibayrenc M, Barnabe C, et al. Chemotherapy with benznidazole and itraconazole for mice infected with different Trypanosoma cruzi clonal genotypes. Antimicrob Agents Chemother. 2003;47:223-30. doi: http://dx.doi.org/10.1128/AAC.47.1.223-230.2003
Veloso VM, Carneiro CM, Toledo MJ, Lana M, Chiari E, Tafuri WL, et al. Variation in susceptibility to benznidazole in isolates derived from Trypanosoma cruzi parental strains. Mem Inst Oswaldo Cruz. 2001;96:1005-11. doi: http://dx.doi.org/10.1590/S0074-02762001000700021
Camandaroba EL, Reis EA, Goncalves MS, Reis MG, Andrade SG. Trypanosoma cruzi: Susceptibility to chemotherapy with benznidazole of clones isolated from the highly resistant Colombian strain. Rev Soc Bras Med Trop. 2003;36:201-9. doi: http://dx.doi.org/10.1590/S0037-86822003000200002
Triana O, Mejía A, Zapata C, Arboleda A, Dib J. Caracterización genética y sensibilidad al benzonidazole de cepas colombianas de Trypanosoma cruzi. Biomédica. 2005;25:82-5.
Luna KP, Hernández IP, Rueda CM, Zorro MM, Croft SL, Escobar P. In vitro susceptibility of Trypanosoma cruzi strains from Santander, Colombia, to hexadecylphosphocholine (miltefosine), nifurtimox and benznidazole. Biomédica. 2009;29:448-55. PMid:20436996
Murta SM, Romanha AJ. In vivo selection of a population of Trypanosoma cruzi and clones resistant to benznidazole. Parasitol. 1998;116:165-71. doi: http://dx.doi.org/10.1017/S0031182097002084
Moreno M, D’ávila DA, Silva MN, Galvão LM, Macedo AM, Chiari E, et al. Trypanosoma cruzi benznidazole susceptibility in vitro does not predict the therapeutic outcome of human Chagas disease. Mem Inst Oswaldo Cruz. 2010;105:918-24. doi: http://dx.doi.org/10.1590/S0074-02762010000700014
Tibayrenc M, Ward P, Moya A, Ayala FJ. Natural populations of Trypanosoma cruzi, the agent of Chagas disease, have a complex multiclonal structure. Proc Natl Acad Sci USA. 1986;83:115-9. doi: http://dx.doi.org/10.1073/pnas.83.1.115
Macedo AM, Machado CR, Oliveira RP, Pena SD. Trypanosoma cruzi: genetic structure of populations and relevance of genetic variability to the pathogenesis of Chagas disease. Mem Inst Oswaldo Cruz. 2004;99:1-12. doi: http://dx.doi.org/10.1590/S0074-02762004000100001
Borst P, Oullette M. New mechanism of drug resistance in parasitic protozoa. Annu Rev Microbiol. 1995;49:427-60. doi: http://dx.doi.org/10.1146/annurev.mi.49.100195.002235
El Fadili K, Messier N, Leprohon P, Roy G, Guimond C, Trudel N, et al. Role of the ABC transporter MRPA (PGPA) in antimony resistance in Leishmania infantum axenic and intracellular amastigotes. Antimicrob Agents Chemother. 2005;49:1988-93. doi: http://dx.doi.org/10.1128/AAC.49.5.1988-1993.2005
Ouellette M, Legare D, Papadopoulou B. Multidrug resistance and ABC transporters in parasitic protozoa. J Mol Microbiol Biotechnol. 2001;3:201-6. PMid:11321574
Singh AK, Papadopoulou B, Ouellette M. Gene amplification in amphotericin B-resistant Leishmania tarentolae. Exp Parasitol. 2001;99:141-7. doi: http://dx.doi.org/10.1006/expr.2001.4663
Some similar items:
- Jorge A. Vega, Simón Villegas-Ospina, Wbeimar Aguilar-Jiménez, María T. Rugeles, Gabriel Bedoya, Wildeman Zapata, Haplotypes in CCR5-CCR2, CCL3 and CCL5 are associated with natural resistance to HIV-1 infection in a Colombian cohort , Biomedica: Vol. 37 No. 2 (2017)
- Winston Rojas, Maria Antonieta Caro, Juan Guillermo Lopera, Omar Triana, Juan Carlos Dib, Gabriel Bedoya, Analysis of polymorphisms in the trypanothione reductase and cruzipain genes in Colombian strains of Trypanosoma cruzi , Biomedica: Vol. 27 No. 1esp (2007): Enfermedad de Chagas
- Omar Cantillo-Barraza, Andrés Gómez-Palacio, Diego Salazar, Ana María Mejía-Jaramillo, Jaime Calle, Omar Triana, Distribution and ecoepidemiology of the triatomine fauna (Hemiptera: Reduviidae) in Margarita Island, Bolívar, Colombia , Biomedica: Vol. 30 No. 3 (2010)
- Carmen Vásquez, Sara Robledo, Jaime Calle, Omar Triana, Identification of new epidemiological scenarios for Chagas disease in the Momposina region, North of Colombia , Biomedica: Vol. 33 No. 4 (2013)
- Patricia Escobar, Katherine Paola Luna, Indira Paola Hernández, César Mauricio Rueda, María Magdalena Zorro, Simon L. Croft, In vitro susceptibility of Trypanosoma cruzi strains from Santander, Colombia, to hexadecylphosphocholine (miltefosine), nifurtimox and benznidazole , Biomedica: Vol. 29 No. 3 (2009)
- Rubén Santiago Nicholls, Zulma Milena Cucunubá, Angélica Knudson, Astrid Carolina Flórez, Marleny Montilla, Concepción Judith Puerta, Paula Ximena Pavía, Acute Chagas disease in Colombia: a rarely suspected disease. Report of 10 cases presented during the 2002-2005 period , Biomedica: Vol. 27 No. 1esp (2007): Enfermedad de Chagas
- Víctor Manuel Angulo, Lyda Esteban, Katherine Paola Luna, Attalea butyracea palms adjacent to housing as a source of infestation by Rhodnius prolixus (Hemiptera: Reduviidae) , Biomedica: Vol. 32 No. 2 (2012)
- Juan Fernando Ríos, Margarita Arboleda, Alba Nelly Montoya, Erika Patricia Alarcón, Gabriel Jaime Parra-Henao, Probable outbreak of oral transmission of Chagas disease in Turbo, Antioquia , Biomedica: Vol. 31 No. 2 (2011)
- Concepción Judith Puerta, Paula Ximena Pavia, Marleny Montilla, Carolina Flórez, Giomar Herrera, Juan Manuel Ospina, Fred Manrique, Rubén Santiago Nicholls, The first case of congenital Chagas’ disease analyzed by AP-PCR in Colombia , Biomedica: Vol. 29 No. 4 (2009)
- Guillermo Mora, María Clara Echeverry, Gustavo Enrique Rey, Myriam Consuelo López, Luisa Fernanda Posada, Fabio Aurelio Rivas, Frequency of Trypanosoma cruzi infection in patients with implanted pacemaker , Biomedica: Vol. 27 No. 4 (2007)
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
